The German Reimbursement Amount Is Decided in the Study Design

Reimbursement negotiations have a reputation as price talks. That misses the point. By the time the GKV-Spitzenverband and a company sit down together, the range of possible outcomes has already been fixed by a different procedure: the G-BA decision on added benefit and on the appropriate comparator therapy. Anyone who wants to influence the price therefore has to start years earlier, at the point where a study's comparator and endpoints are chosen.

The timetable leaves no room to catch up

The chain is tightly scheduled:

• The dossier is due at market launch.
• The benefit assessment is published three months later, usually prepared by IQWiG on behalf of the G-BA.
• The G-BA decision on the extent of added benefit follows no later than six months after launch.
• A six-month negotiation phase under Section 130b SGB V then begins. If no agreement is reached, an arbitration board decides.
• The reimbursement amount applies from the seventh month after first market launch.

Between authorization and an effective reimbursement amount there is therefore a good half year in which the freely set launch price applies. For the argument inside the procedure, though, that window is already history: the dossier was due on day one.

The guardrails tied the amount to the comparator therapy

With the GKV-Finanzstabilisierungsgesetz, the legislator had introduced limits in Section 130b(3) SGB V that coupled negotiating headroom to the decision. Up to 29 July 2026 they applied in this form:

• No added benefit where the appropriate comparator therapy is still under patent or data protection: the reimbursement amount had to produce annual therapy costs at least 10 percent below those of the comparator therapy.
• No added benefit and the appropriate comparator therapy is a medicine whose patent and data protection have expired: the reimbursement amount should not lead to higher annual therapy costs than the comparator therapy.
• Minor or non-quantifiable added benefit and the comparator therapy is still under patent or data protection: the reimbursement amount was not permitted to exceed the annual therapy costs of the comparator therapy.
• Where several alternatives have been determined as appropriate comparator therapy, the most economical one by annual therapy costs applies.

The arithmetic is therefore in plain sight: pricing headroom follows from the extent of added benefit and from the cost of the comparator therapy. Both are outputs of the assessment procedure, and both depend on the question of whom the product was compared against and on which endpoints. In its decision of 7 May 2025, the Federal Constitutional Court left two constitutional complaints against price regulation measures of the GKV-FinStG without success: the guardrails survived constitutional review. It is the legislator that took them back.

The legislator has taken the guardrails back

The GKV-Beitragssatzstabilisierungsgesetz, adopted by the Bundestag on 10 July 2026, was promulgated in the Federal Law Gazette on 29 July 2026 (BGBl. 2026 I No. 228) and has been in force since 30 July 2026. Two of the mechanisms described here are therefore already history, and not in the shape the drafts suggested:

• Section 130b(3) SGB V has not been repealed but restructured. Sentences 2 to 6 were replaced by three new sentences. What fell away is the minimum 10 percent discount for no added benefit against a patent-protected comparator, and the ceiling for minor or non-quantifiable added benefit. What remains is a “shall” rule: where a medicine has no added benefit and cannot be assigned to a reference price group, the reimbursement amount shall not produce higher annual therapy costs than the appropriate comparator therapy. Anyone reading that as a return to the pre-GKV-FinStG state is reading too far.
• The combination discount under Section 130e SGB V is abolished, but the provision itself is not. Section 130e now carries a new subject matter: rebate contracts for medicines with patent-protected active ingredients that have a therapeutically comparable effect. Health insurance funds may define groups of such active ingredients and tender them exclusively and across ingredients, and physicians are bound to the rebated products of a group. Until 31 December 2030 this is limited to five substance classes: JAK, CGRP, PARP, PCSK9 and PD-1/PD-L1 inhibitors.

One further window follows from the act itself: for medicines whose reimbursement amount was agreed or set by the end of 29 July 2026, either contracting party may terminate the agreement or the arbitration award until 1 October 2026 (Section 130b(7a) SGB V as amended).

What this means in practice is not "one constraint less." It means that two calculations sit side by side: one for negotiations conducted under the guardrails, one for everything from 30 July 2026 onwards. The anchor is the same in both cases: the appropriate comparator therapy and the extent of added benefit still determine what is being negotiated at all. What fell away is the quantified minimum discount and one ceiling, not the yardstick. Reading this as free pricing confuses the removal of a cap with the removal of the comparison behind it. And anyone holding combinations in the portfolio is not trading the discount for quiet, but for tender exposure in one of the five named groups.

Three further mechanisms that shift the return

• Combination discount under Section 130e SGB V, gone since 30 July 2026. Medicines with new active ingredients used in a combination named by the G-BA were subject to a 20 percent discount on the manufacturer's selling price excluding VAT, named through the Pharmaceuticals Directive and lifted with future effect once the G-BA determined at least considerable added benefit for the combination. For portfolios with combinations on the market this is a line item that has to be taken back out of the plan, for periods from 30 July 2026 onwards and not only from 2027.
• Revenue threshold for orphan medicines. Under Section 35a(1) sentence 11 SGB V, added benefit is deemed proven upon authorization. If revenue at the expense of statutory health insurance exceeds 30 million euros within twelve months, that presumption falls away and a regular assessment follows. Before the GKV-FinStG the threshold was 50 million euros. In other words, the product's success triggers the procedure that can constrain its price.
• Confidential reimbursement amount, Section 130b(1c) SGB V. For active ingredients first negotiated after 1 January 2025, the reimbursement amount can be exempted from reporting to public price and product directories. The condition is evidence to the GKV-Spitzenverband that the company operates its own pharmaceutical research unit within the scope of SGB V, pursues relevant projects of its own and maintains cooperations with public institutions. The evidence is deadline-bound: within five days of concluding the negotiation, or within six months of first market launch.

Why the German price matters beyond Germany

Germany is one of the most frequently used reference markets in Europe; according to analyses by the WHO Collaborating Center it is part of the reference basket in roughly half of the countries examined. A German amount negotiated low or published early therefore travels into other markets through external price referencing. This is precisely where the confidentiality option earns its value, and precisely why the decision on the launch price is never a purely German one.

For MedTech the same logic sits in a different provision

For methods using high-risk medical devices, Section 137h SGB V applies: when a hospital submits a first request under Section 6(2) KHEntgG for a new reimbursement item, it transmits to the G-BA, in agreement with the manufacturer, the state of scientific knowledge including complete study data. An assessment takes place where the method rests on a new theoretical and scientific concept. Here too, the evidence available at the time of the request decides the revenue path. Supplying it later is not a procedural step.

What to do now

• Work the comparison backwards, for both regimes. For every plausible decision scenario, model the annual therapy costs of the possible comparator therapies, once with the former limits in Section 130b(3) and once with the current “shall” rule. The gap between the two corridors is what the negotiation is actually about.
• Check running agreements against the termination window. Reimbursement amounts agreed or set up to 29 July 2026 can be terminated until 1 October 2026. That is a deadline which expires while people are still debating the legal position.
• Treat the comparator as a pricing decision. Choosing the comparator in the study design is the single most effective pricing decision in the whole life cycle, and it is taken years before the first negotiation round. The restructuring of the guardrails does not change that.
• Update combinations and the revenue threshold. The 20 percent discount drops out of the plan; the success-triggered assessment for orphan medicines stays. Anyone holding active ingredients in one of the five groups named for rebate contracts recalculates there.
• Check the confidentiality option early. Evidence on research and cooperations in Germany cannot be assembled in five days.

Entourage helps pharma, biotech, MedTech and IVD companies do this arithmetic before launch: deriving price corridors for the legal position before and after 30 July 2026, modeling comparator therapy costs, assessing the revenue threshold and the abolished combination discount for the portfolio at hand, and preparing negotiation materials together with the added-benefit argument.

Updated on 3 August 2026 after reading the Federal Law Gazette: the GKV-Beitragssatzstabilisierungsgesetz was promulgated on 29 July 2026 (BGBl. 2026 I No. 228) and has been in force since 30 July 2026. The version of 1 August 2026 stated a start date of 1 January 2027 and a repeal of Section 130b(3) and Section 130e SGB V. Both are corrected: the provisions have applied since 30 July 2026, subsection 3 was restructured rather than repealed, and Section 130e now governs rebate contracts instead of the combination discount. The original version of 14 July 2026 treated the guardrails as a permanent feature.